AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
CRA leading the way in analytics
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...